Effects of metabolic modulation by trimetazidine in patients with chronic heart failure Review article
Article Sidebar
Main Article Content
Abstract
Heart failure causes deep changes both in systemic and in cardiac metabolism. The metabolic modulation is one of the treatment option in these group of patients. Trimetazidine is the metabolic drug which has been reported to exert antiischemic properties without affecting the myocardial oxygen consumption. The results of the previous studies have shown that trimetazidine therapy may be beneficial in terms of improvements in left ventricular function and control of symptoms. In the newest metaanalyses have been shown also trimetazidine therapy reduces the mortality of patients with chronic heart failure.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Kantor P.F., Lucien A., Kozak R. et al.: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000; 86: 580-588.
3. Di Napoli P., Chierchia S., Taccardi A.A. et al.: Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide 2007; 16: 228-236.
4. Di Napoli P., Barsotti A.: Prognostic relevance of metabolic approach in patients with heart failure. Curr. Pharm. Des. 2009; 15: 883-892.
5. Fragasso G., Salerno A., Lattuada G. et al.: Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart 2011; 97: 1495-1500.
6. Liu X., Gai Y., Liu F. et al.: Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc. Res. 2010; 88: 150-158.
7. Belardinelli R., Cianci G., Gigli M. et al.: Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischaemic cardiomyopathy. J. Cardiovasc. Pharmacol. 2008; 51: 611-615.
8. Gunes Y., Guntekin U., Tuncer M. et al.: Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009; 24: 277-282.
9. Tuunanen H., Engblom E., Naum A. et al.: Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008; 118: 1250-1258.
10. Gao D., Ning N., Niu X. et al.: Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011; 97: 278-286.
11. Zhang L., Lu Y., Jiang H. et al.: Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J. Am. Coll. Cardiol. 2012; 59: 913-922.
12. Mann D.L.: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 2002; 91: 988-998.
13. Genessel P., Chodjania Y., Demolis J.L.: Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. Eur. J. Drug. Metab. Pharmacokinet. 2004; 29: 61-68.
14. Di Napoli P., Di Giovanni P., Gaetav M.A.: Trimetazidine and reduction in mortality and hospitalisation in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d’Abruzzo Trimetazidine Trial. J. Cardiovasc. Pharmacol. 2007; 50: 585-589.
15.Fragasso G., Rosano G., Baek S.H. et al.: Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. Int. J. Cardiol. 2012 Oct 13; pii: S0167-5273(12)01244-2 [online: doi: 10.1016/j.ijcard.2012.09.123].